Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Narrower-than-Expected Loss at Dendreon Drives Shares Up
Yahoo/Zacks.com
Tuesday, March 4, 2014 - 10:45am
tags:
Dendreon, earnings
GlaxoSmithKline Plc's 2 Greatest Weaknesses
Motley Fool
Tuesday, March 4, 2014 - 9:19am
tags:
GSK, competition, cash flow
Boston Therapeutics to initiate Phase II clinical study of BTI-320 in U.S.
The Fly on the Wall
Tuesday, March 4, 2014 - 9:18am
tags:
Boston Therapeutics, BTI-320, diabetes
New Roche chairman promises continuity
Reuters
Tuesday, March 4, 2014 - 9:16am
tags:
Roche, Christoph Franz
Forget The Sideshow Distractions And Focus On Galena's Pipeline
Seeking Alpha
Tuesday, March 4, 2014 - 8:44am
tags:
Galena Biopharma, Abstral, NeuVax, cancer pain, breast cancer
Who Stands To Gain With FDA Approval Of OTC Lipitor?
Forbes
Tuesday, March 4, 2014 - 8:38am
tags:
FDA, Pfizer, Lipitor, statins, OTC
Will Pharma's Future Be Based On The Carl Icahn Business Model?
Forbes
Tuesday, March 4, 2014 - 8:37am
tags:
Carl Icahn, Actavis, Forest Labs, M&A
Teva’s New Version of Copaxone Could Be a Tough Bet for Insurers
Wall St Cheat Sheet
Tuesday, March 4, 2014 - 8:30am
tags:
Teva Pharmaceuticals, Copaxone, insurance, MS, multiple sclerosis
Health-Care Deals Make Explosive Start to 2014
Motley Fool
Monday, March 3, 2014 - 9:13pm
tags:
Actavis, Forest Labs, JNJ, AstraZeneca, Bristol-Myers Squibb, Aptalis, M&A
Alexion’s $569,000 Drug Draws Data Demand From U.K. NICE
Bloomberg
Monday, March 3, 2014 - 9:10pm
tags:
Alexion, NICE, Soliris
AbbVie Hepatitis C Combo Cures Almost All in Late Study
Bloomberg
Monday, March 3, 2014 - 6:46pm
tags:
AbbVie, hepatitis C, ABT-450, ABT-267, ABT-333, Gilead Sciences, Bristol-Myers Squibb
Durable melanoma remission seen with Bristol immunotherapy drug
Yahoo/Reuters
Monday, March 3, 2014 - 6:44pm
tags:
Bristol-Myers Squibb, nivolumab, melanoma, metastatic melanoma
Biogen Idec Keeps Momentum Going With MS Drug Tecfidera
Investors.com
Monday, March 3, 2014 - 3:34pm
tags:
Tecfidera, MS, multiple sclerosis, Biogen Idec
3 Surging Biotech Stocks to Watch: OncoSec, Clovis, Dyax
Wall St Cheat Sheet
Monday, March 3, 2014 - 3:33pm
tags:
OncoSec, Clovis Oncology, Dyax
Pfizer Stubs Toe Without Celebrex
Motley Fool
Monday, March 3, 2014 - 12:15pm
tags:
Celebrex, Pfizer, Embeda
EarLens pulls in $36M for infrared hearing aid
Mass Device
Monday, March 3, 2014 - 12:04pm
tags:
EarLens, hearing aid, devices, infrared hearing aid, Medtronic
No merger talk here: Novartis just wants to be friends with Roche, chairman says
Fierce Pharma
Monday, March 3, 2014 - 12:01pm
tags:
Novartis, Roche, M&A
NeoStem: A Potential Blockbuster for Investors
Wall St Cheat Sheet
Monday, March 3, 2014 - 11:57am
tags:
NeoStem, stem cells, AMR-001, heart attacks
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
TheStreet.com
Monday, March 3, 2014 - 11:55am
tags:
glioblastoma multiforme, DCVax, Northwest Biotherapeutics, ICT-107, ImmunoCellular Therapeutics
It's Always Darkest Before The Dawn: Why Vivus Could Double In Three Months And Triple In Twelve
Seeking Alpha
Monday, March 3, 2014 - 11:51am
tags:
Vivus, Qsymia, Stendra

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.